Drug Profile

Tiragolumab - Genentech

Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284

Latest Information Update: 20 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech
Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase II Squamous cell cancer
Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer

25 Sep 2026 Spanish Multidisciplinary Digestive Cancer Groupcompletes a phase-II clinical trials in Squamous cell cancer (Combination therapy, In the elderly, In adults, First-line therapy) in Spain (IV) (NCT05661188) (EudraCT2021-005887-24)
22 Jul 2026 Hoffmann-La Roche completes a phase III SKYSCRAPER-07 trial for Oesophageal cancer(Inoperable/Unresectable, Combination therapy, Monotherapy) in Argentina, Australia, Austria, Belgium, France, Germany, Greece, Hungary, Israel, Italy, New Zealand, Poland, Spain, Switzerland, Turkiye, United Kingdom and USA (NCT04543617)
10 Jun 2026 Hoffmann-La Roche terminates a phase III trial in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Combination therapy) Argentina, Australia, Brazil, China, Italy, Japan, Poland, South Korea, Taiwan, Thailand and Turkey (IV) (NCT06267001)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com